• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌标准腋窝淋巴结清扫术与前哨淋巴结活检的非随机随访比较

A nonrandomized follow-up comparison between standard axillary node dissection and sentinel node biopsy in breast cancer.

作者信息

Konstantiniuk Peter, Schrenk Peter, Reitsamer Roland, Koeberle-Wuehrer Roswitha, Tausch Christoph, Roka Sebastian, Riedl Otto, Poestlberger Sabine, Hecke Dieter, Janauer Michael, Haid Anton

机构信息

University Hospital, Graz, Austria.

出版信息

Breast. 2007 Oct;16(5):520-6. doi: 10.1016/j.breast.2007.04.001. Epub 2007 Jun 12.

DOI:10.1016/j.breast.2007.04.001
PMID:17566737
Abstract

INTRODUCTION

In many countries sentinel node biopsy (SNB) has become the standard of care in breast cancer based on a large number of observational studies but without results from prospective randomized trials. The goal of our study was to evaluate the oncological safety of the SNB in breast cancer in a multicenter, nonrandomized setting with comparable groups.

PATIENTS AND METHODS

Between 1996/05 and 2004/11, 2942 patients from 14 departments in Austria with unicentric, unilateral, invasive disease without neoadjuvant therapy were collected in a database. The recommendations of the Austrian Sentinel Node Study Group were to complete a training period (phase I) with 50 cases of SNB followed by axillary lymph node dissection (ALND) to prove a detection rate of > or = 90% and a false-negative rate of < or = 5%. In the executing period (phase II), SNB was followed by ALND only if the sentinel node (SN) contained metastases. We compared the results on disease-free survival, local recurrence rates, distant recurrence rates and overall survival of both groups. Cases from phases I and II generated groups I (n=671) and 2 (n=2271 cases), respectively.

RESULTS

Overall mean follow-up time: 34.41 months.

CONCLUSION

SNB followed by ALND only in cases with metastases in the SN is a safe procedure and at least equal to ALND in all cases.

摘要

引言

在许多国家,基于大量观察性研究,前哨淋巴结活检(SNB)已成为乳腺癌的标准治疗方法,但尚无前瞻性随机试验的结果。我们研究的目的是在多中心、非随机且具有可比组的情况下评估乳腺癌前哨淋巴结活检的肿瘤学安全性。

患者与方法

1996年5月至2004年11月期间,奥地利14个科室的2942例患有单中心、单侧、浸润性疾病且未接受新辅助治疗的患者被纳入数据库。奥地利前哨淋巴结研究组的建议是,先进行一个为期50例前哨淋巴结活检(SNB)的培训阶段(I期),随后进行腋窝淋巴结清扫(ALND),以证明检出率≥90%且假阴性率≤5%。在实施阶段(II期),仅当前哨淋巴结(SN)存在转移时,在前哨淋巴结活检后进行腋窝淋巴结清扫。我们比较了两组在无病生存率、局部复发率、远处复发率和总生存率方面的结果。I期和II期的病例分别产生了第I组(n = 671)和第2组(n = 2271例)。

结果

总体平均随访时间:34.41个月。

结论

仅在前哨淋巴结有转移的情况下在前哨淋巴结活检后进行腋窝淋巴结清扫是一种安全的手术,并且在所有情况下至少与腋窝淋巴结清扫相当。

相似文献

1
A nonrandomized follow-up comparison between standard axillary node dissection and sentinel node biopsy in breast cancer.乳腺癌标准腋窝淋巴结清扫术与前哨淋巴结活检的非随机随访比较
Breast. 2007 Oct;16(5):520-6. doi: 10.1016/j.breast.2007.04.001. Epub 2007 Jun 12.
2
Multicentric breast cancer: a new indication for sentinel node biopsy--a multi-institutional validation study.多中心性乳腺癌:前哨淋巴结活检的新适应症——一项多机构验证研究。
J Clin Oncol. 2006 Jul 20;24(21):3374-80. doi: 10.1200/JCO.2006.05.7372.
3
Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis.在前哨淋巴结阴性的乳腺癌患者中省略腋窝淋巴结清扫术是安全的:一项长期随访分析。
J Surg Oncol. 2004 Oct 1;88(1):4-7; discussion 7-8. doi: 10.1002/jso.20101.
4
Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.勘误:前哨淋巴结活检阴性的浸润性乳腺癌腋窝复发率:长期随访。
Ann Surg Oncol. 2010 Feb;17(2):552-7. doi: 10.1245/s10434-009-0800-2.
5
[Feasibility of the sentinel node biopsy in breast cancer in case of histological multifocality diagnosis].[组织学多灶性诊断情况下乳腺癌前哨淋巴结活检的可行性]
Gynecol Obstet Fertil. 2009 Jul-Aug;37(7-8):604-10. doi: 10.1016/j.gyobfe.2009.04.021. Epub 2009 Jul 3.
6
Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients.与I级和II级腋窝淋巴结清扫术相比,前哨淋巴结活检与淋巴结阴性乳腺癌患者生存率的提高相关。
Eur J Surg Oncol. 2009 Aug;35(8):805-13. doi: 10.1016/j.ejso.2008.09.006. Epub 2008 Nov 28.
7
Is sentinel lymph node biopsy more accurate than axillary dissection for staging nodal involvement in breast cancer patients?对于乳腺癌患者淋巴结受累情况的分期,前哨淋巴结活检是否比腋窝淋巴结清扫更准确?
Chir Ital. 2007 Sep-Oct;59(5):693-9.
8
Patients with breast cancer and negative sentinel lymph node biopsy without additional axillary lymph node dissection: a follow-up study of up to 5 years.乳腺癌患者前哨淋巴结活检阴性且未进行额外腋窝淋巴结清扫:一项长达5年的随访研究
Oncology. 2007;72(1-2):27-32. doi: 10.1159/000111085. Epub 2007 Nov 12.
9
Prognosis of breast cancer patients treated with sentinel node biopsy in Japan.日本接受前哨淋巴结活检的乳腺癌患者的预后。
Jpn J Clin Oncol. 2004 Aug;34(8):452-6. doi: 10.1093/jjco/hyh077.
10
A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial.一项关于乳腺癌前哨淋巴结活检与腋窝淋巴结清扫术的随机临床试验:Sentinella/GIVOM试验结果
Ann Surg. 2008 Feb;247(2):207-13. doi: 10.1097/SLA.0b013e31812e6a73.

引用本文的文献

1
Omitting SLNB in Breast Cancer: Is a Nomogram the Answer?省略乳腺癌前哨淋巴结活检:列线图能给出答案吗?
Ann Surg Oncol. 2022 Apr;29(4):2210-2218. doi: 10.1245/s10434-021-11007-9. Epub 2021 Nov 5.
2
The efficacy of Tilmanocept in sentinel lymph mode mapping and identification in breast cancer patients: a comparative review and meta-analysis of the ⁹⁹mTc-labeled nanocolloid human serum albumin standard of care.替莫肽在乳腺癌患者前哨淋巴结模式测绘和识别中的疗效:⁹⁹mTc 标记的纳米胶体人血清白蛋白护理标准的比较评价和荟萃分析。
Clin Exp Metastasis. 2012 Oct;29(7):681-6. doi: 10.1007/s10585-012-9497-x. Epub 2012 Jun 23.
3
Sentinel Node Biopsy in Breast Cancer: Clinical Implication - Standard of Care - Fututre Prospects.
乳腺癌前哨淋巴结活检:临床意义 - 护理标准 - 未来前景
Breast Care (Basel). 2009;4(3):195-202. doi: 10.1159/000218329. Epub 2009 Jun 17.
4
Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms.乳腺癌中的淋巴转移:细胞和分子机制的重要性及新见解
Clin Exp Metastasis. 2007;24(8):619-36. doi: 10.1007/s10585-007-9123-5. Epub 2007 Nov 6.